Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Clinical Investigation of Active Implantable Medical Devices: An Overview of ISO 16571:2016
Guidance for Planning, Conducting, and Reporting Clinical Studies for AIMDs in Accordance with International Standards
Scope and Applicability
ISO 16571:2016 (adopted in Canada as CAN/CSA-ISO 16571:16) provides comprehensive guidance for the clinical investigation of active implantable medical devices (AIMDs). The standard is intended for sponsors, investigators, ethics committees, and regulatory bodies involved in the design, conduct, monitoring, and reporting of clinical studies for AIMDs. It covers all phases of clinical investigation from initial feasibility through post-market clinical follow-up.
The standard applies to devices such as cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), neurostimulators, implantable drug pumps, and cochlear implants. ISO 16571:2016 complements ISO 14155 (Clinical investigation of medical devices for human subjects) by addressing device-specific considerations for active implants, including interaction with electromagnetic environments, battery longevity, and surgical implantation.
Tip: When applying ISO 16571:2016, sponsors should also reference ISO 14971 (Risk Management for Medical Devices) and ISO 14708 (Implants for surgery — Active implantable medical devices — General requirements) to ensure comprehensive coverage of safety and performance aspects.
Technical and Organizational Requirements
Clinical Investigation Plan (CIP)
The standard details the essential components of a Clinical Investigation Plan for AIMDs, including clear endpoints, subject selection criteria, implantation procedures, follow-up schedules, and compliance with applicable regulations. Table 1 summarizes the key elements required in a CIP according to ISO 16571:2016.
| Element | Description | Specific Considerations for AIMDs |
|---|---|---|
| Study Objectives | Primary and secondary endpoints with statistical hypotheses | Device performance (e.g., pacing thresholds, sensing) and clinical outcomes (e.g., morbidity, mortality) |
| Subject Selection | Inclusion/exclusion criteria, number of subjects, and demographics | Anatomical suitability, concomitant medications, life expectancy compatible with battery longevity |
| Implantation Procedure | Surgical or interventional technique, required tools, and operator qualifications | Sterilization, implant location, lead placement, tunneling routes |
| Follow-up Schedule | Clinical and device evaluations at specified intervals | Remote monitoring, battery status, lead integrity, and patient clinical status |
| Safety Reporting | Plans for adverse event documentation, severity classification, and reporting timelines | Events related to implant procedure, device malfunction, electromagnetic interference, or explantation |
| Data Management | Data collection, storage, source verification, and statistical analysis plan | Automated device data retrieval, interrogation logs, and cybersecurity considerations |
| Quality Assurance | Monitoring, auditing, and regulatory compliance | Alignment with ISO 14155 and regional regulations (e.g., EU MDR, Health Canada, FDA) |
Risk Management Integration
ISO 16571:2016 emphasizes the need to incorporate risk management throughout the clinical investigation. The standard requires that the clinical investigation plan reference the findings from risk analysis (per ISO 14971) and include risk controls that are verified and validated in the clinical setting. Specific attention must be given to risks unique to active implants, such as lead fracture, inflammation due to foreign body response, or overstimulation of tissues.
Warning: Failure to properly integrate risk management with clinical investigation may lead to underreporting of adverse events and compromise subject safety. Risk controls should be clearly linked to clinical endpoints in the study design.
Ethics and Informed Consent
The standard mandates that every clinical investigation receive approval from an independent ethics committee before enrolment. Informed consent documents must cover device-specific risks, alternative treatments, implantation and explantation procedures, and post-study access to therapy. For vulnerable populations (e.g., patients requiring emergency implant), special safeguards apply.
Implementation Highlights for Sponsors and Investigators
Study Phases and Customization
ISO 16571:2016 defines three main phases for AIMD clinical investigation:
- Feasibility studies: Small-scale early studies to refine device design and implantation technique.
- Pivotal studies: Full-scale controlled trials to confirm safety and effectiveness for market approval.
- Post-market clinical follow-up (PMCF): Long-term monitoring of device performance in the general population.
The standard allows flexibility in study design, recognizing that some devices may not be amenable to randomized controlled trials due to ethical reasons. In such cases, well-planned single-arm studies with objective performance criteria are acceptable.
Implementation Success: A robust PMCF plan aligned with ISO 16571:2016 can facilitate timely detection of long-term device failures and support proactive regulatory submissions for design improvements.
Data Integrity and Device Interfacing
Because AIMDs generate continuous physiological data, the standard provides guidance on data validation, secure transfer to electronic data capture systems, and reconciliation with clinical observations. Sponsors should implement measures to ensure data integrity, including regular audits of implanted device interrogation files against case report forms.
Compliance and Regulatory Notes
Conformity Assessment
ISO 16571:2016 is not a stand-alone conformity assessment standard but is intended to support regulatory submissions for AIMDs. In jurisdictions that adopt it as a harmonized standard (e.g., EU MDR or Health Canada requirements), compliance with ISO 16571:2016 can demonstrate that the clinical investigation meets accepted quality and safety benchmarks. Notified bodies and regulators will assess the investigation against these requirements.
Adverse Event Reporting
The standard adopts a structured classification of adverse events based on severity (device-related vs. procedure-related, serious vs. non-serious) and prescribes time frames for expedited reporting. Sponsors must establish a systematic process to monitor, collect, and report events to ethics committees and regulatory authorities.
Important Compliance Note: Non-compliance with reporting timelines can result in study suspension, regulatory fines, or rejection of clinical data for marketing authorization. The clinical trial registry number must be included in all submissions.
Global Harmonization
ISO 16571:2016 aligns with the principles of the International Medical Device Regulators Forum (IMDRF) and is intended to facilitate mutual recognition of clinical data among different regulatory systems. Sponsors conducting multinational studies can benefit from using the standard as a common framework, but regional variations (e.g., US 21 CFR Part 812, EU MDR Annex XV) must still be observed. Health Canada explicitly recognizes CAN/CSA-ISO 16571:16 as a reference for clinical evidence of AIMDs.
Q: Is ISO 16571:2016 applicable to non-implantable active medical devices?
A: The standard is specifically written for active implantable medical devices. For non-implantable devices (e.g., external pacemakers, infusion pumps), reference ISO 14155 and relevant device-specific product standards.
A: The standard is specifically written for active implantable medical devices. For non-implantable devices (e.g., external pacemakers, infusion pumps), reference ISO 14155 and relevant device-specific product standards.
Q: Can a feasibility study be omitted if data from a similar predicate device is available?
A: Yes, provided the predicate device’s clinical data adequately address the safety and performance questions of the new device. A detailed justification based on risk analysis must be included in the clinical investigation plan. Regulators may still require a small feasibility study to verify changes in materials or software.
A: Yes, provided the predicate device’s clinical data adequately address the safety and performance questions of the new device. A detailed justification based on risk analysis must be included in the clinical investigation plan. Regulators may still require a small feasibility study to verify changes in materials or software.
Q: How does the standard address cybersecurity for implantable devices with external communication?
A: The standard recognizes the growing importance of cybersecurity. It advises that the clinical investigation plan include assessments of data security and patient privacy, especially during remote monitoring and software updates. Risk management must address potential cybersecurity threats as part of the overall device safety evaluation.
A: The standard recognizes the growing importance of cybersecurity. It advises that the clinical investigation plan include assessments of data security and patient privacy, especially during remote monitoring and software updates. Risk management must address potential cybersecurity threats as part of the overall device safety evaluation.
Q: What is the recommended follow-up duration for a post-market clinical follow-up study?
A: ISO 16571:2016 does not prescribe a fixed duration; it depends on the device’s lifecycle, expected failure modes, and battery longevity. Typically, PMCF studies continue until a statistically meaningful number of events (e.g., device failures, explants) have been observed, usually at least 3–5 years for implantable devices.
A: ISO 16571:2016 does not prescribe a fixed duration; it depends on the device’s lifecycle, expected failure modes, and battery longevity. Typically, PMCF studies continue until a statistically meaningful number of events (e.g., device failures, explants) have been observed, usually at least 3–5 years for implantable devices.
This article is intended as a general overview and is not a substitute for the full text of ISO 16571:2016 (CAN/CSA-ISO 16571:16). Readers should consult the official standard for complete requirements. For specific regulatory guidance, always refer to the applicable health authority.
© 2026 International Standards Publishing. All rights reserved.